NCT07020819View on ClinicalTrials.gov

An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (FORWARD Study)

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 30, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

June 30, 2028

Conditions
Guillain-Barre Syndrome
Interventions
DRUG

Tanruprubart

Solution for IV infusion.

All Listed Sponsors
lead

Annexon, Inc.

INDUSTRY